Clinical Trials & Research

As part of the comprehensive service that Southern Neurology provides, we also participate in investigator driven and industry sponsored clinical trials.

This provides our patients with the opportunity to have access to potential new therapies. In general, Southern Neurology is compensated by the pharmaceutical companies on a per-subject basis for each clinical trial to cover the costs of investigator time, ancillary personnel, facilities use, tests and procedures.

Below is a list of clinical trials that we are currently or imminently involved in as part of an international multi-centre collaboration. Generally, patients who wish to take part in these trials will need to be assessed and managed by one of our Neurologists to ensure that all inclusion criteria are met for the particular trial.

Please contact our Clinical Research Coordinators at clinical.trials@southern-neurology.com.au if you would like to find out more.

Browse the Research and related Publications by our Doctors here.

Featured care areas

We provide expert, patient-centred care for complex neurological conditions.

Studies open to recruitment

Alzheimer's Disease

MK-2214-004

A Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of MK-2214 in Participants With Early Alzheimer's Disease

Indication Mild cognitive imapirment or mild dementia due to AD

CN012-0051

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated With Mild to Moderate Alzheimer's Disease (MINDSET 1)

Indication Mild or moderate AD

I9M-MC-ONAA

A Phase 1, Open Label, Multiple-Dose Study to Assess the Changes in Cerebrospinal Fluid Biomarkers for Alzheimer's Disease Following Treatment With LY3439539 in Participants With Symptomatic Alzheimer's Disease

Indication Symptomatic AD

Multiple Sclerosis

CLOU064P12301

A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Remibrutinib in Patients With Secondary Progressive Multiple Sclerosis

Indication Secondary progressive MS

BP46016

A Multi-center, Double-blind, Placebo-controlled, Phase II Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489, a Monoacylglycerol Lipase Inhibitor, as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis

Indication Progressive MS

MRX-4TZT-05

A Multicenter, Randomized, Fixed Sequence, Cross-over Study to Assess the Safety, Tolerability, and Pharmacokinetics of MRX-4TZT TDS (Tizanidine Transdermal Delivery System) versus Oral Tizanidine in Multiple Sclerosis Patients with Established Spasticity

Indication MS

Parkinson's Disease

BN44715

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early-Stage Parkinson's Disease

Indication Early-stage PD